Procter & Gamble Health Announces Strong Growth with Sales Up 20% in Q4; PAT Rises 55%
Procter & Gamble Health Ltd. today announced its financial results for the fourth quarter and financial year ended March 31, 2026, reporting significant year-over-year growth across key metrics.For the quarter ending March 31, 2026, the company recorded sales of ₹365 crores, marking a 20% increase compared to the previous year. Profit After Tax (PAT) for the same quarter reached ₹95 crores, showing a 55% jump year-over-year.
The company also reported robust full-year performance for the Financial Year ending March 31, 2026. Consolidated sales reached ₹1385 crores, representing a 16% increase compared to the comparable 12-month period in the preceding year. Correspondingly, PAT for the fiscal year stood at ₹327 crores, reflecting a 30% rise against the comparable 12 months.
The sustained growth across the company was attributed to strong brand fundamentals and a positive consumer response to new product innovations. The rise in PAT was led by superior brand building activities, supported by strengthened supply chain and go-to-market capabilities.
| Metric | Q4 Ended March 31, 2026 | Growth vs. Prior Year |
|---|---|---|
| Sales | ₹365 crores | Up 20% |
| Profit After Tax (PAT) | ₹95 crores | Up 55% |
| Metric | FY Ended March 31, 2026 | Growth vs. Comparable Period |
|---|---|---|
| Sales | ₹1385 crores | Up 16% |
| Profit After Tax (PAT) | ₹327 crores | Up 30% |
Milind Thatte, Managing Director of Procter & Gamble Health Limited, emphasized that the strong year was driven by continued investment across the value chain. He highlighted that the strategy is centered on a focused portfolio of quality, trusted, and highly recommended brands, ensuring sustainable, balanced growth and value creation for stakeholders.
The company continues to drive growth through innovative products, including the new Livogen Iron Gummies, an easy-to-consume, strawberry-flavored iron supplement, and Neurobion Nerve Pain Relief Cream, a specialized topical solution for nerve-related pain.
In terms of shareholder returns, the Board of Directors recommended a final dividend of ₹ 45/- per Equity Share for the Financial Year ended March 31, 2026. Including the interim dividend of ₹160 per share paid on February 27, 2026, the total dividend payout for the fiscal year will amount to ₹205 per share, subject to approval by the Shareholders at the ensuing 59th Annual General Meeting.
Furthermore, the company continues its commitment to community welfare through its Corporate Social Responsibility initiative, P&G Sehat. This initiative focuses on providing healthcare access and raising healthcare awareness in underserved communities and has impacted over 15 lakh lives since its inception.
PGHL Stock Price Movement
Shares of Procter & Gamble Health Limited today slipped by 1.12% to settle at ₹5652.5. The stock traded on a volume of 15,617 shares, contributing to the company’s downward movement for the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.